BeOne Medicines (ONC) Payables (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Payables data on file, last reported at $423.5 million in Q1 2026.

• Quarterly Payables rose 16.2% year-over-year to $423.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $423.5 million (up 16.2% YoY) and the FY2025 annual result came in at $479.0 million, down 61.88% from the prior year.
• Payables declined to $423.5 million in Q1 2026 per ONC's latest filing, from $479.0 million in the prior quarter.
• Across five years, Payables topped out at $1.3 billion in Q4 2024 and bottomed at $234.4 million in Q2 2022.
• The 5-year median for Payables is $333.0 million (2024), against an average of $427.2 million.
• The widest annual swing landed in 2024, when Payables jumped 298.76%; it then sank 61.88% in 2025.
• Tracing ONC's Payables over 5 years: stood at $294.8 million in 2022, then rose by 6.9% to $315.1 million in 2023, then jumped by 298.76% to $1.3 billion in 2024, then slumped by 61.88% to $479.0 million in 2025, then declined by 11.58% to $423.5 million in 2026.
• Per Business Quant, the three latest ONC Payables figures stand at $423.5 million (Q1 2026), $479.0 million (Q4 2025), and $1.2 billion (Q3 2025).

Peer Comparison